ERBB2 and breast carcinoma: Advances in digital pathology and artificial intelligence now enable quantitative pathomics analysis, offering new opportunities for precise prediction and prognostic assessment.<h4>Methods</h4>In this retrospective study, 162 HR-positive, HER2-negative breast cancer patients treated with NAC between 2014 and 2021 were included.